One To Watch

ABL Bio

Company Overview

A South Korean clinical-stage biotech whose proprietary Grabody bispecific antibody platform has attracted deals with Eli Lilly, GSK, Sanofi, and Merck, positioning ABL Bio as one of Asia's most partner-validated antibody engineering platforms. Founded in 2016 and listed on KOSDAQ, ABL Bio has pivoted from single-asset developer to platform licensor, with its Grabody technology now spanning oncology, neurodegeneration, obesity, and muscle disorders. The November 2025 Lilly deal — worth up to $2.602 billion — is the clearest signal yet that the platform's modularity resonates well beyond its Korean origins.

Headquarters and Global Presence

ABL Bio is headquartered in Seongnam, South Korea, in the greater Seoul metropolitan area. The company operates primarily from its Korean base but maintains an increasingly global footprint through clinical partnerships and its Neok Bio spinout, which is advancing US Phase I trials.

Founding and History

Sang Hoon Lee founded ABL Bio in February 2016, building the company around a proprietary bispecific antibody engineering thesis from inception. It listed on the KOSDAQ exchange and has grown into a multi-billion-dollar market cap company without being acquired. The spinout of Neok Bio in 2025 — funded with $75 million to run bispecific ADC programs into US trials — marks the company's most significant structural evolution since its founding.

Therapy Areas and Focus

ABL Bio's pipeline concentrates on two major fronts: immuno-oncology, where multiple checkpoint-engaging bispecifics are in active clinical development, and neurodegeneration, where the Grabody-B blood-brain barrier shuttle platform addresses one of CNS drug delivery's most intractable problems. The Lilly collaboration additionally opens Grabody's application to obesity and muscle disorders — disease areas with substantial commercial pull. This breadth is less a scattered strategy than a deliberate demonstration that the same antibody-engineering logic can unlock multiple therapeutic spaces.

Technology Platforms and Modalities

The Grabody platform is ABL Bio's central asset: a suite of bispecific antibody formats engineered to engage two targets simultaneously with controlled geometry and affinity. Grabody-B specifically shuttles therapeutic antibodies across the blood-brain barrier by co-engaging a BBB receptor alongside the primary CNS target — a mechanism that addresses the delivery barrier that has historically made CNS biologics impractical. The company is also extending Grabody architecture into antibody-drug conjugates through the Neok Bio spinout, combining bispecific targeting precision with cytotoxic payload delivery. That Lilly, GSK, Sanofi, and Merck have each independently licensed or collaborated on Grabody applications provides external validation of the platform's versatility across modalities.

Key Pipeline and Programs

ABL301 (partnered with Sanofi as SAR446159) is a bispecific antibody targeting alpha-synuclein and LRP1, using Grabody-B to achieve brain penetration for Parkinson's disease — a program that drew Sanofi into a global licensing deal in June 2024. The asset represents ABL Bio's most advanced CNS program and the commercial logic behind the subsequent GSK Grabody-B deal for broader neurodegeneration indications.

ABL503 (ragistomig) is a PD-L1 x 4-1BB bispecific in clinical development for solid tumors, and ABL111 (givastomig) is a TIGIT x PD-1 bispecific also advancing in oncology; both sit in the company's immuno-oncology cluster. ABL001 (tovecimig), a DLL4 x VEGF-A bispecific, rounds out the IO franchise, with a clinical collaboration with Merck announced in October 2024 to evaluate it alongside pembrolizumab.

Through Neok Bio, ABL206 (NEOK001) and ABL209 (NEOK002) are bispecific ADCs slated for US Phase I trials in 2026, with initial data anticipated in 2027 — the company's first direct entry into the ADC space that has dominated oncology deal-making in recent years.

Recent Developments

The headline event of the past twelve months is the November 2025 Grabody platform license with Eli Lilly, valued at up to $2.602 billion with $55 million in combined upfront and equity payments. In April 2025, ABL Bio signed a worldwide licensing agreement with GSK for Grabody-B in neurodegenerative diseases, extending the platform's CNS credibility beyond the Sanofi Parkinson's deal. The Neok Bio spinout, funded at $75 million, was structured specifically to advance bispecific ADC programs ABL206 and ABL209 into US Phase I trials during 2026. Taken together, these moves reflect a deliberate strategy to both advance proprietary assets and generate platform licensing revenue in parallel.

Key Personnel

Sang Hoon Lee serves as Founder and Chief Executive Officer, having established ABL Bio in February 2016 with a founding thesis around bispecific antibody platforms; he has led the company through KOSDAQ listing and into a series of major global pharma partnerships. The company's deal cadence across Lilly, GSK, Sanofi, and Merck reflects the kind of sustained business development execution that typically requires close CEO involvement in a founder-led biotech of this size.

Strategic Partnerships

ABL Bio's partnership portfolio now spans four of the world's largest pharmaceutical companies. The Lilly agreement (November 2025, up to $2.602 billion) covers Grabody platform expansion into obesity, muscle disorders, IO, and ADCs; the GSK deal (April 2025) licenses Grabody-B for neurodegeneration globally. Sanofi holds rights to ABL301/SAR446159 for Parkinson's disease following a June 2024 licensing deal, while Merck entered a clinical trial collaboration and supply agreement in October 2024 for tovecimig combined with pembrolizumab. WuXi Biologics serves as a manufacturing and development partner on bispecific antibody and IO programs.

FAQ Section

ABL Bio has systematically licensed the Grabody platform to major pharma partners — Lilly, GSK, Sanofi, Merck — while simultaneously advancing proprietary clinical assets and spinning out Neok Bio to run the ADC franchise. This parallel-track model generates upfront and milestone-linked revenue without requiring full internal commercialization, a pragmatic structure for a KOSDAQ-listed company seeking global reach. The $2.602 billion ceiling on the Lilly deal alone signals how the market is pricing Grabody's versatility.

Delivering biologics to the brain has been a fundamental limitation for CNS drug development; most antibodies are too large to cross the blood-brain barrier at therapeutically relevant concentrations. Grabody-B bypasses this by engineering a bispecific format that co-engages a BBB receptor to actively transport the antibody across the barrier alongside the disease target, enabling antibody-based CNS therapy that would otherwise be impractical. The fact that both Sanofi (for Parkinson's alpha-synuclein) and GSK (for broader neurodegeneration) have independently licensed this mechanism underscores its potential as a platform, not just a one-disease fix.

Most bispecific developers are indication-focused — building one or two formats for a specific tumor or disease setting. ABL Bio's Grabody architecture is intentionally modular, designed to be reconfigured across oncology (checkpoint combinations, ADC targeting), CNS (BBB delivery), and now metabolic disease (obesity, muscle disorders under the Lilly deal). The spinout of Neok Bio for bispecific ADCs rather than integrating them internally suggests ABL Bio views each application as a distinct business unit — a structure that preserves capital discipline while maximizing platform reach.

ABL301, developed as SAR446159 under Sanofi's partnership, is a bispecific antibody targeting both alpha-synuclein — the protein that aggregates in Parkinson's disease — and LRP1, a BBB receptor used as a transport mechanism via Grabody-B. Sanofi acquired global rights through a licensing deal that drove ABL Bio's shares up nearly 30% in June 2024. The program represents the first clinical test of whether Grabody-B's BBB shuttle can deliver meaningful central exposure in a neurodegenerative disease context, making its early readouts highly watched beyond ABL Bio itself.

ABL Bio's IO pipeline spans at least four clinical-stage bispecifics: tovecimib (ABL001, DLL4 x VEGF-A), givastomig (ABL111, TIGIT x PD-1), ragistomig (ABL503, PD-L1 x 4-1BB), and the Merck collaboration exploring tovecimib with pembrolizumab in solid tumors. The target combinations — particularly TIGIT/PD-1 and PD-L1/4-1BB — reflect a deliberate focus on next-generation checkpoint synergies beyond the PD-1 monotherapy landscape. Neok Bio's ADC programs ABL206 and ABL209 extend this into bispecific-targeted cytotoxic payloads, adding a further dimension to the cancer strategy.

ABL Bio is firmly in the clinical stage across multiple programs simultaneously, with its most advanced assets in Phase I and Phase II trials and platform revenue now flowing through licensing deals. The most immediate catalysts are the initiation of US Phase I trials for Neok Bio's ADCs (ABL206 and ABL209) during 2026 and initial data readouts anticipated in 2027. Progress disclosures on SAR446159 from Sanofi and early data from the Merck pembrolizumab combination study also represent near-term clinical watchpoints.

ABL Bio's platform story hinges on several near-term tests:

Phase I data for Neok Bio ADCs (ABL206/ABL209) in 2027 will be the first read on whether bispecific targeting improves the ADC therapeutic window.
SAR446159 clinical progression under Sanofi will validate or challenge the Grabody-B BBB shuttle in a human CNS setting — a high-stakes read for the GSK deal's long-term value too.
The Merck pembrolizumab combination with tovecimib needs to differentiate in a crowded IO combination space to sustain commercial interest.
Deal concentration risk: with Lilly, GSK, Sanofi, and Merck each holding platform or asset licenses, any major partner's pipeline reprioritization could materially affect ABL Bio's milestone revenue stream.
Currency and geopolitical exposure as a KOSDAQ-listed company executing primarily US and European clinical programs.

Want to Update your Company's Profile?